We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Rentschler to Manufacture Faron Product Traumakine®

Rentschler to Manufacture Faron Product Traumakine®

Rentschler to Manufacture Faron Product Traumakine®

Rentschler to Manufacture Faron Product Traumakine®

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rentschler to Manufacture Faron Product Traumakine®"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Faron Pharmaceuticals Ltd. and Rentschler Biotechnologie GmbH have announced that they have signed a manufacturing and supply agreement for the Faron product FP-1201 that is also known as Traumakine®.

The active pharmaceutical ingredient of the FP-1201 is recombinant human interferon beta-1a (IFN-beta 1a) that was first produced by Rentschler already in the late 1980’s. According to the agreement Rentschler will become the sole global manufacturer of IFN-beta 1a for Faron and also manufacture Faron’s proprietary bulk drug product.

Traumakine® is formulated so that it is stable at room temperature and readily available for critical care doctors at intensive treatment units. Traumakine® is meant to prevent vascular leakage in patients with acute lung injuries (ALI) and its more severe form ARDS. This prevention is critical to sustain respiratory function in ALI/ARDS patients. Financial details of the agreement were not disclosed.

"Our aim is to build a specialty pharma product for critical care doctors treating ALI/ARDS patients at intensive care units", comments Faron’s CEO Markku Jalkanen.

"We are very satisfied with our collaboration with Rentschler and their experience with manufacturing and formulation of interferon-beta. This agreement allows Faron to move to final clinical development stage of Traumakine®, and to file marketing authorization application to European Medicines Agency (EMA) following the conduction of the pan-European pivotal trial in years 2012-14", continues Jalkanen.

"Rentschler has the longest history of IFN-beta manufacturing and formulation development in the world, and is therefore the best partner for Faron’s Traumakine® project", comments Klaus Schoepe, Senior Vice President Client Relations of Rentschler.

"We bring to this product our process of IFN-beta manufacturing together with our capacity to finalize the Faron product and are very motivated to aid Faron in bringing Traumakine® to global markets in this new indication ALI/ARDS", continues Schoepe.